“…Carbenoxolone (CBXH 2 ) is a semi-synthetic, commercially available anti-inflammatory drug, a succinyl derivative of GE. It was developed in the early 1960s for the management of peptic ulcers (Brown et al, 1959;Doll et al, 1965;Horwich & Galloway, 1965), but later in vitro and in vivo studies have shown its efficacy in the treatment of metabolic disorders (Dhanesha et al, 2012;Nuotio-Antar et al, 2007;Pivato et al, 2006), allergy (Heo et al, 2007), virus infection (Partridge & Poswillo, 1984) and possible application in neuroscience (Chepkova et al, 2008;Spataro et al, 2004;Tovar et al, 2009;Xu et al, 2014). Both CBXH 2 and GE are practically insoluble in water.…”